期刊
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
卷 13, 期 9, 页码 1842-1851出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138920112800958814
关键词
Herpes simplex virus; oncolytic viruses; tumor microenvironment; angiogenesis; extracellular matrix; cytokines; immune response
资金
- Ohio State University Comprehensive Cancer Center
- Dardinger Center for Neuro-Oncology and Neurosciences
- NINDS/NIH [1R01NS064607, 1K01NS059575, 1R21NS056203, R21NS063290, U01NS061811]
- NCI/NIH [R01CA150153, R21CA133663, R01CA114004]
- NIH/NCI [P01CA089248]
- NIH/NIMH [R21MH082421]
- Alliance for Cancer Gene Therapy
Oncolytic virotherapy with mutants derived from Herpes simplex virus (HSV) type 1 exhibit significant antitumor effects in preclinical models. Several mutants have now been tested in clinical trials for a variety of cancer types, and all have been found to be safe. While there have been hints of antitumor efficacy with prolonged survival in some cases compared with historical controls, dramatic responses have been elusive. We review the clinical experience published to date and discuss some of the biologic factors that may be limiting for virus infection and spread, as well as new strategies currently under development to enhance antitumor efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据